Pharming Group N.V. announces 14 poster presentations by the Company or its collaborators regarding leniolisib and RUCONEST® at the International Primary Immunodeficiencies Congress (IPIC) and the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in November.

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of November:

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September:

Pharming Group N.V. announces that Pharming’s management will attend the following investor conferences in the month of June:

Pharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries will attend the H.C. Wainwright BioConnect Investor Conference 2023 on May 2, 2023 in New York and will take part in a fireside chat at 11:00 ET/17:00 CEST.

Pharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries and Chief Financial Officer, Jeroen Wakkerman will attend the Van Lanschot Kempen Life Sciences Conference on April 25 and 26, 2023 in Amsterdam, the Netherlands.

Pharming Group N.V. announces that Pharming’s management will attend the 22nd Annual Needham Virtual Healthcare Conference April 17 - 20, 2023.

Pharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries, and Chief Commercial Officer, Stephen Toor, will attend the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days, April 3 - 4, 2023 in New York.

Presentation to highlight data from the ongoing long-term open-label extension study of leniolisib, a PI3Kδ inhibitor under investigation for APDS, a rare primary immunodeficiency.

Pharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries, and Chief Medical Officer, Anurag Relan, will attend the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, California, November 7-10, 2022.